Abstract. The present study aimed to detect the expression of somatostatin (SS) and SS receptor (SSTR)1-5 in tissues from patients with endometriosis (EMS). Reverse transcription-quantitative polymerase chain reaction analysis was applied to examine the expression of somatostatin gene in ectopic endometrial cells (EECs). The expression of somatostatin receptor 1-5 in the ectopic endometrium (EE), eutopic endometrium and normal endometrium and their association with EMS staging were determined by immunohistochemistry. The results indicated that the expression of SS in EECs was significantly higher compared with that in the control group. SSTR1-5 were expressed in the EE tissues from 30 patients with EMS, and the positive rates were 43.3, 70.0, 53.3, 50.0 and 96.7%, respectively, which were closely associated with EMS staging of the patients. The positive rates of SSTR1-5 expression in the eutopic endometrium from 12 patients with EMS were 33.3, 41.7, 58.3, 58.3 and 83.3%, respectively, while the positive rates of SSTR1-5 expression in the normal endometrium from 14 women without EMS were 7.1, 7.1, 21.4, 28.6 and 64.3%, which were lower than the positive rates of SSTR1-5 in the EE (43.3, 70, 53.3, 50 and 96.7%) and eutopic endometrial cells (33.3, 41.7, 58.3, 58.3 and 83.3%). In conclusion, SS was highly expressed in EECs. SSTR1-5 were expressed in the ectopic as well as eutopic endometrium, and low or moderate expression of SSTR1-4 and high expression of SSTR5 were detected in the ectopic and eutopic endometrial tissues, while low expression of SSTR1-4 and partial expression of SSTR5 were detected in normal endometrium. The positive rates of expression of SSTR1-5 in the EE cells and eutopic endometrium were higher than those in the normal endometrium. The expression of all the subtypes of SSTR in the EE tissues was closely associated with EMS staging.
Introduction
The incidence of endometriosis (EMS) has increased in recent years, and has become one of the most common gynecological diseases affecting numerous women at childbearing age (1) . The present treatment method for EMS mainly includes hormone therapy and surgery since the e�fi cacy o� drug treat� since the e�fi cacy o� drug treat� the e�ficacy o� drug treatment is not ideal and the disease easily recurs (2) . Somatostatin (SS) is a peptide hormone with extensive physiological effects. It is a natural polypeptide hormone containing 14 or 28 amino acids, which widely occurs in human endocrine and exocrine systems, and has extensive biological effects, which are mainly inhibitory (3) . SS and its analogues have been used to treat neurological diseases, including Alzheimer's disease, chorea and epilepsy, tumor types, including pituitary, pancreatic islet cell and carcinoid tumor; and certain gastrointestinal diseases, including gastric ulcer, stomach bleeding and digestive tract ulcer, acute pancreatitis and bleeding from esophageal varices (4) (5) (6) . The physiological functions of SS include hormone regulation, inhibition of cell proliferation, neurotransmitter release, inhibition of gastric acid, secretion of pepsin and gastrin, reduction o� splanchnic blood flow, as well as the inhibition of the release of insulin-like growth factor (IGF)-1, platelet-derived growth factor, epidermal growth factor, white blood cell interleukin (IL)-6 and interferon (IFN)-γ (4, 7) .
Numerous studies have indicated that SS inhibits the proliferation of tumor cells (8, 9) . It acts by binding to specific cell surface receptors, SS receptors (SSTRs), which occurs as 5 SSTR subtypes named as SSTR1-5 (10) . SSTR exists in a wide variety of neuroendocrine tumors and tumors of the nervous system (11) . Certain studies have reported the expression of SSTR in endometrial and ovarian cancer (12, 13) . However, few studies have focused on the expression of SSTR in EMS lesions. The present study was designed to detect the expression of the SS and SSTR1-5 genes in EMS tissue and its association with the disease.
Materials and methods
Tissue samples. The EMS tissues and cells were extracted from 30 female patients during gynecological laparotomy or laparoscopic surgeries at the Department of Obstetrics and Gynecology, Xiangya Hospital of Central South University (Changsha, China) between July 2009 and December 2012. Cell separation and culture. To establish in vitro cultures, the method reported previously was used (4,7), with certain modifications: The obtained tissues were washed three times with PBS, dissected it into 0.5-1 mm 3 pieces and placed in a 20-ml centrifugal tube. Following addition of 2.5-5.0 volumes of 0.1% collagenase and 0.25% trypsin digestion solution and even mixing, the samples were incubated in a water bath at 37˚C with continuous agitation �or 50�100 min in NE group and 80-120 min in the EE group. Subsequently, DMEM was added to stop the digestion, followed by repeated pipetting of the samples. The cells were then filtered through a 100�mesh stainless steel net. The filtrate, mainly containing the mesenchymal and epithelial cells, was centrifuged at 170 x g for 10 min, the supernatant was removed, and the pellet was resuspended in DMEM/F12 with 15% fetal bovine serum, and after the cell count was determined under trypan blue staining, the cell concentration in the suspension was adjusted to 5x10 5 cells/ml. The cells were inoculated into a culture dish and cultured in an incubator with 5% CO 2 at 37˚C with the medium replaced once every 2-3 days until cell convergence was reached in the primary culture. The cell shapes and growth were observed with an inverted microscope and images were captured.
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Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The PCR primers were designed based on the human SS mRNA sequences from GenBank, and GAPDH was used as a control. The primers were synthesized by Nanjing GenScript Biotechnical Co., Ltd (Nanjing, China) and had the following sequences (in 5'-3' direction): SS upstream, GCT GCT GTC TGA ACC C and downstream, CGT TCT CGG GGT GCC ATA G (product length, 138 bp); GAPDH upstream, TGC ACC ACC AAC TGC and downstream, GGC ATG GAC TGT GGT CAT GAG (product length, 87 bp). Total RNA was extracted using TRIZOL reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. A cDNA Reverse Transcription lit (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used �or reverse transcription. Briefly, 3 µg total RNA (0.5 µg/µl), 1 µl Oligo dT Primer, 1 µl dNTP Mixture (both Takara Biotechnology Co., Ltd., Dalian, China) and RNase-free doubly distilled (dd)H 2 O (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) were mixed with the total mixture o� 10 µl. The mixture was stirred at 70˚C �or 5 min and then the 10 µl mixture, 4 µl 5X PrimeScript II Bu��er, 0.5 µl RNase inhibitor, 1 µl PrimeScript II RTase and 4.5 µl RNase��ree ddH 2 O were mixed followed by a reaction at 45˚C �or 45 
Results
Expression of SS mRNA in the different groups. The relative expression of SS mRNA in the cells of the EE and NE groups was automatically output by MxPro software (Fig. 1) . Results demonstrated that the expression o� SS was significantly higher in the EE group compared with that in the NE group (P<0.05).
E xpression of S ST R su bt ypes in E M S t issu es.
Immunohistochemical analysis revealed that in ectopic endometrial cells, SSTR was mostly located in the cytoplasm and cell membrane. Fig. 4 ; Table II) .
Discussion
SS is a natural polypeptide that is extensively distributed in the digestive and nervous system, and exhibits several biological 
effects (16). The clinical application of SS is restricted, as natural SS has a short half-life in vivo of 4 min only (17)
. The SS analogue (SSTA) has the advantages of a long half-life, relatively long-lasting effect, high selectivity and ease of application (18) . Numerous types o� cancer cell, inflammatory cell and immune cell (e.g., lymphocytes, phagocytic cells, endothelial cells and thymus cells) also produce SS (19) . Growth hormones IGF, IL-1, IL-6, TNF-α and IFN-γ, and other growth factors and cytokines as well as glucocorticoid, androgen and estrogen may increase the expression of SS, whilst insulin and leptin may inhibit its expression (4,7). The intracellular factors regulating the expression of SS mainly include cyclic adenosine monophosphate (AMP), Ca
2+
, cyclic guanine monophosphate and nitric oxide (19) . cAMP has a promoting effect on the expression and secretion of the SS gene, which resembles a signal transduction pathway to regulate the function of SS (19) .
The RT-qPCR results of the present study indicated that the expression o� SS mRNA in EMS cells was significantly higher compared with the normal endometrial cells. Sbracia and Scarpellini (20) demonstrated that the occurrence of EMS is associated with immune mechanisms. The activity of intraperitoneal mononuclear macrophages in EMS patients is increased, and they secrete large amounts o� inflammatory mediators, including IL-1, IL-6 and TNF-α, which creates an environment that drives EMS cell proliferation (21) . These factors also promote the expression of the SS gene (22) . The present study indicated that the expression of the SS gene is elevated in EMS cells, and this increase is likely to be associated with the occurrence and development of the disease.
Numerous studies have indicated that SS is an important hormone regulatory peptide that restrains cell proliferation and differentiation, and which may be utilized to inhibit the proliferation and angiogenesis of tumor cells (23) . The mecha-23). The mecha-3). The mechanism underlying the inhibitory effect of SS mainly includes direct inhibition and also indirect effects (24) . After binding and activation, SS, SSTA and SSTR may exert anti-proliferative effects through 4 major signaling pathways (4): i) Via the cAMP pathway to change cAMP metabolism. The decrease in cAMP leads to inhibition of cell proliferation and affects protein synthesis (19) ; ii) changes in intracellular Ca 2+ to reduce the membrane permeability regarding Ca 2+ , inhibit Ca 2+ influx and block Ca 2+ -mediated intracellular processes (6); iii) phosphate protein kinase pathways: After the SSTR binds to ligands, tyrosine kinase is inactivated by dephosphorylation to inhibit protein kinases, e.g., mitogen-activated protein kinase (MAPK), leading to inhibition of cell proliferation (25, 26) ; iv) the phosphatidylinositol-3-kinase (PI3K) pathway: SSTA inhibits the proliferation of tumor cells through the inhibition of PI3K (27) . The indirect inhibitory effects of SSTA comprise activation of Fas, Caspase-8 and MAPK pathways mediated via receptors, blocking cell cycle progression from G1 phase to S phase, inhibition of the cell proliferation and promotion of apoptosis (28, 29) . A further indirect inhibitory effect of SSTA is the inhibition of angiogenesis (30, 31) . The ectopic endometrium as autografts rather relies on vascular support, and angiogenesis is crucial to the development of EMS (32), and thus the occurrence and development of EMS may be inhibited through the above mechanisms by using SSTA, which requires to be �urther verified.
SS acts through binding to specific receptors on the cell surface and SSTR is a membrane protein receptor, which is divided into 5 subtypes and has 7 transmembrane domains (10) . According to the similarity and varying affinity towards SSTR, SS may be divided two types: i) High a�finity to SSTR, Table I . Positive rate of expression of SSTR subtypes in endometriotic tissues and its association with clinical staging. including SSTR2, SSTR3 and SSTR5; ii) weaker affinity, with substrates including SSTRl and SSTR4. SSTRl, SSTR2
and SSTR5 mainly mediate the anti-proliferative effect of SS. SSTR is distributed in all of the major human lymphoid Table II . Expression of SSTR subtypes in endometrial tissues of ectopic (n=30), eutopic (n=12) and control endometrium (n=14) groups. organs, including thymus, spleen, lymph nodes, tonsils and gut-associated lymphoid tissues (33) . SSTR, expressed as different subtypes in different lesion tissue types, occurs in a wide variety of neuroendocrine tumors and tumors of the nervous system; it is differentially expressed in human tumor and healthy tissues (11, 34) . It has been reported that SSTR is also expressed in non-neuroendocrine tumor tissues; e.g., >50% of breast cancer and 40% of colorectal cancer tissues were reported to be positive for SSTR (35, 36) . SSTR is also expressed in liver, prostate and pancreatic cancers, as well as in gastric mucosa-associated lymphoid tissue lymphoma and its metastases (37) (38) (39) (40) . Schulz et al (41) detected the expression of SSTRl, -2 and -3 in 12 patients with cervical carcinoma and the positive rate was 38, 57 and 43%, respectively, while they were negative for the expression of SSTR4 and -5; furthermore, SSTR1-5 was expressed in 18 patients with endometrial carcinoma with positive rates of 32, 39, 43, 4 and 4%, respectively. Although a large number of studies have assessed SSTA and SSTR in other systems, studies have not focused on the expression of SSTR in EMS lesion tissues (35) (36) (37) (38) (39) (40) . Green et al (13) have assessed the expression of SSTR2 in the endometrium during the human menstrual cycle using the immunohistochemistry and RT-qPCR, and their results indicated that SSTR2 was expressed throughout the menstrual cycle. Fasciani et al (42) discovered that SSTRl, SSTR2 and SSTR5 were highly expressed in ovarian and peritoneal endometrial lesions using immunohistochemistry and RT-qPCR. Furthermore, a cell experiment indicated that the octreotide inhibits the migration and proliferation of endometrial cells (42) . Annunziata et al (43) reported that SSTR1-5 were expressed in EMS tissues and cells, and that in normal eutopic endometrial cells, mainly SSTR1 was expressed, while the expression of STR3 and -2 was low and SSTR4 and -5 were not expressed.
Immunohistochemical staining (n) --------------------------------------------------------------------------------------
The immunohistochemical results of the present study indicated that SSTR1-5 were expressed in EMS tissues from 30 patients at the rates of 43.3, 70, 53.3, 50 and 96.7%, respectively, which was significantly associated with the clinical stage of the patients. However, in previous results of Fasciani et al (42) and Annunziata et al (43) , the expression of SSTR1-5 was not significantly associated with the clinical stage. It was hypothesized that the difference may be due to the different clinical samples and populations, which require more studies �or confirmation. In the present study, the positive expression rate of SSTR1-5 in eutopic endometrium from 14 EMS patients was 33.3, 41.7, 58.3, 58.3 and 83.3%, respectively, whilst that in normal endometrial tissue was lower than that in ectopic (43.3, 70 .0, 53.3, 50.0 and 96.7%) and eutopic endometrium at 7.1, 7.1, 21.4, 28.6 and 64.3%, respectively. The results verified that SSTR1�5 was expressed in the ectopic and eutopic endometrium groups and thus provides a therapeutic basis the use of SSTA for EMS.
The results of the present study indicated that the positive expression rate of SSTR1-5 in EMS and eutopic endometrium cells was higher than that in normal endometrium, suggesting that a similarity between eutopic and EMS cells and a difference from normal endometrium, further confirming the 'eutopic endometrium determinism' theory. Therefore, the detection of SSTR expression in the eutopic endometrium is o� clinical significance.
Various clinical studies have confirmed that the SSTA, including octreotide, has inhibitory effects on pancreatic cancer, breast cancer, neuroendocrine tumors and carcinoid tumors (4) (5) (6) . Scintigraphy (SS receptor imaging, SS receptor scintigraphy) with radiolabeled SSTA has been used for diagnosing and locating tumors (44) . Radiolabeled SS analogues bind to SSTR-positive tumors and help in making a definite diagnosis (45) . Fasciani et al (42) injected 111 In-diethylene triamine pentaacetic acid octreotide in 8 EMS patients pre-operatively, and when scanning was performed after 12 h, stronger signals were detected in the pelvic cavity of 6 patients and weaker signals in that of 2 patients, and no adverse reactions were encountered. By scintigraphy using radiolabeled SSTA, EMS may be located and diagnosed, EMS lesions that B ultrasound and computed tomography cannot detect in the pelvic cavity and intestinal duct may be discovered and it is possible to make an auxiliary diagnosis for patients with EMS-induced chronic pelvic pain (46) .
Previous studies have indicated that in certain types of cancer tissue with low or no expression of SSTR, including pancreatic, gastric, colorectal and ovarian cancer, the expression levels of SSTR may be improved by transfection of SSTR gene to thus improve the e�ficacy o� SSTA (47, 48) . For endometrial cells with low expression levels of SSTR, high expression of SSTR may be genetically induced (43) , thus increasing the likelihood for the successful treatment of EMS using SSTA.
The present study indicated that SS and its receptor are expressed in EMS tissues or cells and enhanced the knowledge in the field, on which novel methods �or the diagnosis and treatment of EMS using SSTR gene transfection and SSTA approaches may be based.
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